Abstract: A method for generating interference signals and a device to carry out said method, in which an interference signal (1) is added in a signal combination and separation network (3) with a desired signal (4) that carries a test message, the sum signal being sent to a device being tested (5). The interference signal (1) is generated with a single source connected to a signal divider and conditioner block (7) that attenuates additional interference produced by the source of generation of interference signals (1), while providing as many interference signals (1) as the device (5) under test has antennas (Rx, Rx/Tx), and in which each interference signal (1) is sent to a respective amplification and isolation block (8), which adjusts the power level of the interference signal (1) and attenuates the reverse intermodulation products produced by the transmission of signals by the device (5) under test.

Abstract: The present invention relates to a solid pharmaceutical composition containing candesartan cilexetil as active ingredient and a stabilizing agent selected from the group consisting of esters of saturated fatty acids and monohydroxy alcohols, esters of hydroxycarboxylic acids and monohydroxy alcohols, ethers of C1-C4 monohydroxy alcohols and C2-C9 polyhydroxy alcohols, saturated fatty acid alkaline salts, panthenol, and/or mixtures thereof. The invention also relates to a process for its preparation and its use for formulation of oral solid dosage forms of candesartan cilexetil. The active substance in the compositions comprising the stabilizing agent exhibits good stability over time.

Abstract: Compounds of general formula (I): where A, E, G, X, Y and the bond - - - take various meanings are of use in the preparation of a pharmaceutical formulation, for example in the treatment of a disease in which GSK-3 is involved, including Alzheimer's disease or the non-dependent insulin diabetes mellitus, or hyperproliferative disease such as cancer, displasias or metaplasias of tissue, psoriasis, arteriosclerosis or restenosis.

Abstract: Compounds of general formula (I): where A, E, G, X, Y and the bond - - - take various meanings are of use in the preparation of a pharmaceutical formulation, for example in the treatment of a disease in which GSK-3 is involved, including Alzheimer's disease or the non-dependent insulin diabetes mellitus, or hyperproliferative disease such as cancer, displasias or metaplasias of tissue, psoriasis, arteriosclerosis or restenosis.